BioNTech
Update in progressBNTX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
BioNTech SE and its subsidiaries develop and commercialize immunotherapies in Germany. The company markets BNT162, an mRNA vaccine for SARS-CoV-2, and maintains a broad oncology program with multiple candidates in various phases, including Gotistobart, Pumitamig, Trastuzumab pamirtecan, BNT113, BNT116, BNT326/YL202, and Autogene cevumeran. It also pursues vaccines and therapies for infectious diseases and is based in Mainz, founded in 2008.
Company score
- Sentiment
- 0.81
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.01
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.35
- Governance
- -0.05
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.35
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationGermany
- CEODr. Ugur Sahin M.D.
- Founded2008
- Employees7,807
- Websitewww.biontech.de
Identifiers
- ISINUS09075V1026
- FIGIBBG00Q70B3V1
- LEI894500UZJ5LG1F8J1U58
- CUSIP09075V102
- CIK0001776985